VHIRhttp://www.vhir.org/salapremsa/noticies/noticies_paginacio.asp?page=1&mv1=5&mv2=3es-esIRHUV15The Spanish Parkinson Federation recognizes a study by Dr. Vila as the best research paper (18/12/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=267&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0267\2014_0267_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Dr. Miquel Vila, head of the Neurodegenerative Diseases Group of the VHIR, and member of CIBERNED, has been recognized as the best research paper in the VII edition of the Spanish Parkinson Federation (FEP) awards. The jury recognized the article ‘Lewy Body Extracts from Parkinson Disease Brains Trigger a-Synuclein Pathology and Neurodegeneration in Mice and Monkeys’, published last march in the scientific journal Annals of Neurology and presented by Dr. Miquel Vila, among the 21 articles presented coming from research centers and hospitals from all over Spain. The same scientific journal, Annals of Neurology, and its editorial board had already awarded Dr. Vila’s article two months ago, as best article of 2014. The study shows that pathological forms of the alfa-synuclein protein present in the brain of deceased Parkinson Disease (PD) patients were capable of initiating a PD-like pathological process in mice and primates. For the authors, these findings provide new information on how the disease is initiated and amplified. For Dr. Gurutz Linazasoro, president of the FEP jury, “the work can explain the mechanism of neuronal degeneration and the progression of the symptoms. The most direct potential consequence is the identification of new targets for neuroprotective therapies”. Moreover, he assures that “we have to stress that the work is fruit of the collaboration effort of different groups, national and international, and makes an example of the way of making big science in the 21st century”. </td></tr></table>comunica@vhir.org (VHIR)Thu, 18 Dec 2014 00:00:00 GMTKilometric donations (17/12/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=266&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0266\2014_0266_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Recovering from an IronMan competition can be a challenge by itself but for Chronic Fatigue Syndrome (CFS) patients the real challenge is every day life. The consequences of participating in one of the most physically demanding races are very similar to the symptoms that CFS patients experiment. This illness affects up to 3% of the population. With this idea in mind, 8 participants from the IronMan race in Barcelona have started the #IMHeart project. Using a Smartphone app kilometers will be accumulated whenever the users are exercising, later those kilometers generated will be ‘donated’ to CFS research projects. The kilometers covered will be given to the study coordinated by Dr. Jesús Castro, from the Chronic Fatigue group at VHIR, headed by Dr. José Alegre, titled “CFS and fibromyalgia in teens: emergent entities that determine academic failure and deterioration of life quality”. The project is drove in collaboration with several national and international research and university centers such as Hospital Sant Joan de Déu, Centro Médico Delfos, Hospital Clínic and University of Bristol (UK). The ‘Associació Catalana d’Afectats de Fibromialgia, SFC I SQM’ (ACAF) also gives support to the cause. For participating in the donation it is necessary to get registered in the web: http://app.iwopi.org/login, and download the Runkeeper app for Smartphone. Once some distance is covered, you can donate the kilometers through the iWOPI web to the CFS project. Through the iWOPI platform, the kilometers given by the donors will be accumulated. The challenge thrown is to achieve 150.000 km in three months. Those kilometers (or miles) can be earned either running, walking, swimming or riding a bike. The ultimate objective is to be on the move for those who cannot do it every day. </td></tr></table>comunica@vhir.org (VHIR)Wed, 17 Dec 2014 00:00:00 GMTThe musical group 'Els amics de les Arts' has raised 40000 Euros for cancer research (15/12/2014)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2014&num=263&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0263\2014_0263_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The Catalan band ‘Els amics de les Arts’ has raised 40 thousand Euros in two benefit concerts organized by Antonio Bosch Foundation in order to contribute to child cancer research in Vall d’Hebron Institute of Research (VHIR), group headed by Dr. Sánchez de Toledo. The group threw its second and last benefit concert last Thursday in Sant Cugat’s Teatre-Auditori. They also had some friends joining them on stage, such as Joan Dausà, Roger Mas, Cybee, Els Catarres, Blaumut and Mamzelles. Els amics de les Arts have thanked trough their web the unselfish collaboration they have received saying “all the work that means organizing this kind of concert pays off when you find yourself on stage singing someone else’s song that you love, or when you hear one of your songs but with a voice that’s not your own, or when your fingers are literally trembling accompanying someone who has written songs that are very important for you”. VHIR’s researchers were invited by the band to this second concert which was full of emotion and complicity between the band and the invited musicians. The first benefit concert was in Olot, at Braus Square, where the band presented its new album ‘Només d’entrar hi ha sempre el dinosaure’. All the money raised during the concerts will go to the three research lines of VHIR’s Translational Research in Child Cancer Group, with whom Foundation A. Bosch is collaborating in order to get better diagnosis and therapies. Foundation A. Bosch was created in 2004 by Noel Alimentària, with the aim of promoting medical research for child diseases and lupus. </td></tr></table>comunica@vhir.org (VHIR)Mon, 15 Dec 2014 00:00:00 GMTThe editor-in-Chief of 'The Lancet' closes Vall d'Hebron 18th Annual Conference (12/12/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=262&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0262\2014_0262_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The editor-in-Chief of the prestigious scientific journal The Lancet, Dr. Richard Horton, has come to Vall d’Hebron to give the closing speech of the Vall d’Hebron Universitary Hospital 18th Annual Conference which ended this Friday, December 12th. With an enthusiastic speech with references to Picasso and Salvador Espriu, Horton has reflected on the challenges of the future, that in his opinion are global vision of health, science, society, solidarity and sustainability. The conference has ended the 8th VHIR Scientific Conference. Before the The Lancet’s editor conference, VHIR’s director, Dr. Joan Comella, has presented the Institute’s annual results. He has highlighted the good results on scientific production that puts VHIR’s researchers in first-line research, with an accumulated impact factor during 2014 of 3.500. He has also presented the great economic results of the centre, obtained thanks to competitive calls, clinical trials, agreements with industry and donations. The hospital’s manager, Dr. José J. Navas, has praised the daily work carried out by VHIR’s researchers to improve people’s health and life quality, and has remarked the importance of innovation to speed up this goal. VHIR grants Once again, the Institute has awarded the predoctoral grants during the Annual Conference, but for the first time in this 18th edition, ‘VHIR’s friends’ have participated in the ceremony. The Institute’s donors will fund for 3 years the predoctoral training of Casandra Riera, researcher from the Bioinformatic Group, and Luz Jubierre<span style=" font-size: 8pt</td></tr></table>comunica@vhir.org (VHIR)Fri, 12 Dec 2014 00:00:00 GMTOpening of the VHIR's 8th Scientific Conference (11/12/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=261&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0261\2014_0261_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Today has started the 8th VHIR’s Scientific Conference. During two days, 41 physicians in training, 36 predoctoral researchers, 9 postdoctoral researchers and 9 researchers in nursing will present what they are currently investigating at Vall d’Hebron Institute of Research (VHIR). On this edition the sessions will take place in different places: the Auditorium of the 10th floor of the hospital will host the first part of the predoctoral sessions and all the nursing presentations; the second part of the predoc sessions will take place at the conference room of the Collserola building; the conference room of the ground floor of the hospital will host the presentations of the physicians in training; and the auditorium of the Pavelló Docent building will host the presentations of the postdoctoral researchers. The best presentations will be awarded at the 18th Annual Conference, that will take place on Friday at the Pavelló Docent. On the ceremony, will be also recognized the winners of the VHIR predoctoral grants, the ‘VHIR friends’ predoctoral grants, and the post-mir grant by the Obra Social ‘la Caixa’. The annual lecture will be pronounced by the editor-in-chief of the prestigious scientific journal The Lancet, Dr. Richard Horton. The title of his speech is “Science and charity: reflections on the purpose of medicine and the meaning of health”. - Program of the 8th VHIR Scientific Session <p style=" text-align: left; text-indent: 0px; padding:</td></tr></table>comunica@vhir.org (VHIR)Thu, 11 Dec 2014 00:00:00 GMTWorld experts in endoscopic surgery meet in Vall d'Hebron (10/12/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=260&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0260\2014_0260_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The World Institute for Digestive Endoscopy Research (WIDER-BCN) from Hospital Universitary Vall d’Hebron has organized a two day International Course: Natural Orifice Translumenal Endoscopy Surgery (NOTES) dedicated to transluminal endoscopy trough natural orifices. Over 130 doctors, surgeons and researchers from all over the globe participated in this 8th edition, directed by WIDER’s leader, Dr. José Ramón Armengol, and Doctors Manuel Armengol and Antonio J. Torres García. The meeting has become the world’s most outstanding forum about advanced endoscopic and transluminal surgery. WIDER center was created in 2008, as an agreement between Generalitat de Catalunya, Obra Social “la Caixa”, Vall d’Hebron Universitary Hospital and VHIR to encourage and promote research in endoscopic surgery and implement a specific and autonomous program inside VHIR’s structure for this area. Specifically, research in endoscopic and surgery technology, experimental endoscopic research using NOTES methodology, clinical innovation research and training in medical-surgical digestive endoscopy in the different specialties. WIDER institute, which is led by Dr. José Ramon Armengol, aims to clinical application, animal experimentation and national and international diffusion of their activities. One of these activities is the NOTES Course that in its 8th edition offered presentations about simulations such as Single port access, NOTES experimental, NOTES clinic, NOTES applied to obesity and transrenal surgery. In endoluminal endoscopy new diagnostic alternatives were presented in bilipancreatic diseases, and in endomulnial therapeutic specialty Poem’s new techniques with Acalasia treatment and new techniques in tumor resection. In this edition two surgeries were broadcasted, one of them from the clinical side, endoscopy, Acalasia patients and tumoral and polypoid deformation of the digestive tract. The other video was broadcasted from VHIR’s ‘Animal Facility’, very sophisticated bile and pancreatic drainage interventions using ecoendoscopy. All the patients who were operated have evolved without complications and were sent home (4 acalaseis, 6 resections and sewing of the gastric and colonic wounds). The course’s first night a dinner-symposium was thrown in CosmoCaixa, presided by the Health Consellery representative, Joaquim Casanova, and La Caixa’s representative, Enric Banda. In this event two endoscopy experts, Kiyokazu Nakajima and Sergey Kantsevoy, spoke about non-sedated colonoscopy and automatic use of CO2 in endoluminal surgery and esdoscopy. </td></tr></table>comunica@vhir.org (VHIR)Wed, 10 Dec 2014 00:00:00 GMTThe Chronic Fatigue group presents the results of a clinical trial and a biological study with antioxidants (09/12/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=259&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0259\2014_0259_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The Chronic Fatigue group at Vall d’Hebron Institute of Research (VHIR), led by Dr. José Alegre, presented together with the Catalan company VITAE the preliminary results of a clinical trial and a biological study with Reconnect®, based on the combination of antioxidants Coenzyme Q10 + NADH, with the aim of improving the symptoms of the Chronic Fatigue Syndrome (CFS).  The clinical trial has demonstrated that the synergetic combination of both natural antioxidants improves the symptoms of the disease and also recovery of biomarker parameters. VHIR researchers conducted the Phase II, double blinded and randomized clinical trial, in 73 patients diagnosed with chronic fatigue syndrome at Vall d’Hebron University Hospital. During 8 weeks, half of them were given CoQ10 + NADH and the other half, placebo, in order to compare the effect of the drug on the cardiac adaptations of patients with chronic fatigue. Furthermore, researchers also measured the intensity of fatigue, pain and sleep problems, before and after the treatment. The results have been recently published in the journal Antioxidants &amp; Redox Signaling. Dr. Jesús Castro, principal investigator of the Chronic Fatigue group, highlights five benefits of the study: “patients who received this combination of antioxidants showed a significant fatigue reduction, an increase in antioxidant levels and recovery of energy and mitochondrial function in ATP form, an increase of synthase citrate enzyme and a reduction in oxidized lipids; all of them key factors that can contribute to the illness symptomatology”. The next step for VHIR’s researchers and VITAE Co. will be to increase to 300 CFS patients more enrolled in the clinical trial from the Chronic Fatigue Clinical Unit at the Vall d’Hebron Hospital. </td></tr></table>comunica@vhir.org (VHIR)Tue, 9 Dec 2014 00:00:00 GMTThe loss of the gene RHOA contributes to the progression of colorectal tumors and metastasis (05/12/2014)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2014&num=258&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0258\2014_0258_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Researchers of the Oncology Molecular group from CIBBIM- Nanomedicine at Vall d’Hebron Institute of Research (VHIR) have discovered that the loss of a gene, called RHOA, enhances tumor progression and metastasis in colon and rectal cancer. The study also reveals the mechanism of action of this gene, whose role is completely different in other types of cancer. The results have been published in Nature Communications. The main author of the study, Dr. Diego Arango, has studied the role of RHOA since 2005, when he discovered with another international research group that it was one of the genes that presented more differences in its expression between patients with good and poor prognosis. Based on this first study, the aim of the research that now has been published, was to determinate whether the loss of RHOA levels is the cause (or one of the causes) of the poor prognosis of the patients. In order to prove it, researchers inactivated RHOA in the gut of mice that had started the tumorogenesis, which is the process by which cancer is produced. “We discovered that the animals died earlier and had more and bigger tumors”, explained Dr. Arango, head of the Oncology Molecular group, and researcher of the CIBER of Bioengineer, Biomaterials and Nanomedicine. To confirm the results, they also developed in vitro techniques, which proved that the loss of RHOA is associated to major tumor proliferation and cellular differentiation. After discovering RHOA’s function in colorectal cancer tumors, VHIR’s team sought to determine if the gene’s absence also had a similar effect in metastasis. Using a murine study, the researchers detected that RHOA’s inactivation made colon cancer cells more metastatic. According to the researcher, that explains why “in the metastasis samples from patients with colorectal cancer we have found less RHOA expression than in the primary tumors”.&nbsp; </td></tr></table>comunica@vhir.org (VHIR)Fri, 5 Dec 2014 00:00:00 GMTVall d'Hebron's Market and VHIR promote a solidary calendar (04/12/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=257&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0257\2014_0257_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Vall d’Hebron Market has edited a solidary 2015 calendar, and the money collected will be used in heart disease research in Vall d’Hebron Institut de Recerca (VHIR). The calendar costs one euro, and can be bought in any of the market stands. With this action the market workers wanted to do their bit in heart diseases research, as it causes thousands of deaths every year. Overall, there have been produced 2.000 calendars, drown by Mario Tarragó and designed by Jordi Santamaria. Dr. David García Dorado is head of the Cardiovascular Diseases group at VHIR, and works in prevention, diagnosis and treatment of the heart diseases. The researchers also coordinate actions in sanitary education, healthy lifestyle promotion and create new diagnosis and therapeutic tools and new care systems. </td></tr></table>comunica@vhir.org (VHIR)Thu, 4 Dec 2014 00:00:00 GMTBarcelona's Medical Board acknowledges Vall d'Hebron professionals (03/12/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=256&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0256\2014_0256_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Barcelona’s Medical Board has awarded five Vall d’Hebron professionals with its 2014 Professional Excellence Award: Dr. Fernando Azpiroz, head of the Physiology and Pathophysiology of the Digestive Tract Group of the Vall d’Hebron Institut de Recerca (VHIR), Dr. Francesc Bosch, head of VHIR’s Experimental Hematology Group, Dr. Josep Àngel Bosch, Internal Medecine expert, and member of the Systemic Diseases Group, Dr. Manuel Matas, specialist in Angilology and Vascular and General surgery, and Dr. Marius Morlans, retired Nephrology specialist. The professional association has also recognized the work carried out by the Cardiology Unit in Vall d’Hebron’s Universitary Hospital, headed by Dr. David García Dorado, head of VHIR’s Cardiovascular Diseases Group. Two of VHIR’s group heads have been awarded Dr. Fernando Azpiroz graduated in Medicine and Surgery in 1977, from Universidad de Valladolid. 9 years later he got his PhD from Universidad Complutense de Madrid, and in 2011 he was appointed Professor in Medicine by the Science and Education Ministry. His first experience in Vall d’Hebron was in 1986, as an associated researcher at the Digestive Tract Research Unit. Before he had been doing his residence in Hospital Clínico San Carlos in Madrid, and had also worked for three years as a researcher in Mayo Clinic at Rochester, Minnesota. Nowadays he leads the hospital’s Digestive Unit, and also VHIR’s research group, composed by over 25 professionals. They are doing first line research in fields such as: abdominal distension, microbiota, or irritable bowel syndrome, among others.&nbsp; Dr. Francesc Bosch graduated in Medicine and Surgery from Universitat de Barcelona in 1988. After finishing his residence in Hematology at Barcelona’s Hospital Clínic, he got his PhD in 1997 also from Universitat de Barcelona. His studies about cyclin D1 overexposure in lymphoproliferative syndromes lead him to take a 2 year postdoctoral position at Columbia University, New York. He returned to Barcelona in the year 2000, and 9 years later he was announced Head of the hemathology Unit of Vall d’Hebron, and Head of the Experimental Hematology research Group. The group is formed by over 20 professionals, and leads three research lines: chronic lymphatic leukemia, lymphoproliferative syndromes and myelodysplastic syndromes. </td></tr></table>comunica@vhir.org (VHIR)Wed, 3 Dec 2014 00:00:00 GMT'Wounded memories, rebel bodies' arrives to Terrassa delivered by Dr. Josep Gámez (02/12/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=255&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0255\2014_0255_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Dr. Josep Gámez, head of Vall d’Hebron Institut de Recerca (VHIR) Peripheral Nervous System group, made the inaugural speech of the exhibition ‘Wounded memories, rebel bodies: itineraries against oblivion’. Until December 4th, exhibition room Cima of the patronal Cecot building will hold this exhibition that has toured Spain, showing the nude bodies of people who suffered the disease. The VHIR researcher spoke about the need to establish a comprehensive care system to help these people, who now, decades after overcoming the disease, deal with what is known as post-Polio Syndrome. Nowadays professionals in Vall d’Hebron look after over 200 people with this illness. The photographic exhibition, with images by Bernat Millet, explores poliomyelitis’s memory through the bodies of people who went through the illness, its consequences, and further effects. The exposure’s goal is to raise awareness in society about the illness trough the scars and stories of the people pictured. </td></tr></table>comunica@vhir.org (VHIR)Tue, 2 Dec 2014 00:00:00 GMTVHIR signs an agreement with the Universidad Técnica de Ambato (02/12/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=251&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0251\2014_0251_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Vall d’Hebron Institute of Research (VHIR) has signed an alliance with the Universidad Técnica de Ambato, in Ecuador, to promote the exchange of professors and students, organize training activities, and aid in the execution of common research projects. Dr. Juan Ángel Recio, head of the VHIR Melanoma Group, and Mileydis Perez, researcher of the same group, will be in charge of monitoring the activities and common projects between the two centers. As a first project, researchers of both centers will study the role in metabolism of the enzymatic complex aldehyde dehydrogenase (ALDH) and the resistance to therapeutic treatments of the tumor stem cells. This research, that will last 3 years, aims to determinate the biomolecular function of the ALDH isoforms in the control of the cellular death of the tumor stem cells in lung cancer and identifying new targets for the treatment of the illness. </td></tr></table>comunica@vhir.org (VHIR)Tue, 2 Dec 2014 00:00:00 GMTVHIR and Interarts begin a project to ensure sexual and reproductive rights of immigrant population in Spain (30/11/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=253&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0253\2014_0253_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Researchers from Vall d’Hebron Research Institut (VHIR) and the Programa de Salut Internacional de l’Institut Català de la Salut (PROSICS) along with Interarts, presented the project DECIDES ESPAÑA. The aim of this initiative is to improve equity in access to and exercise of sexual and reproductive rights of young and women of migrant origin in Spain. Until October 2015, the experts involved in the project will develop the following activities: an assessment on equity in access to Sexual and Reproductive Health services, whose results will be published on December 18th&nbsp; at the Vall d'Hebron infrastructure; educational materials that will strengthen the cultural competencies of health sector professionals as well as of key actors in this field; 10 training workshops on the use of the educational material by professionals from the health sector; 5 awareness-raising activities geared towards civil society on sexual and reproductive rights and equality in a context of cultural diversity; 8 presentations on the subject&nbsp; in a context of cultural diversity and equality; as well as 1 workshop of audiovisual creation and reflection on this field for young immigrants. The&nbsp; group of professionals on Infectious Diseases from VHIR and PROSICS have over 20 years of extensive experience in the field of intercultural medicine, both at local / national and international level. The project was presented on November 19th at Casa del Mar in Barcelona, at the conference entitled "Women Sexual and Reproductive Rights. A transnational vision of Female Genital Mutilation". DECIDES ESPAÑA is co-funded by the Financial Mechanism of the European Economic Area (EEA Grants) which aims at contributing to the reduction of economic and social inequalities, and to strengthening the relationships between donor states (Iceland, Liechtenstein and Norway) and beneficiary states (17 EU Member States). The Plataforma de ONG de Acción Social is the Operatoring Agency of the Programa de Ciudadanía Activa (Active Citizenship Programme) which is endowed with EUR 4.6 million for the strengthening of NGOs and their contribution to social justice and sustainable development. Follow the Ciudadanía Activa program on Twitter and Facebook. </td></tr></table>comunica@vhir.org (VHIR)Sun, 30 Nov 2014 00:00:00 GMTVHIR and the Innovative Medicine Initiative present the future call for proposals (28/11/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=252&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0252\2014_0252_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> On the 26th of November, Vall d’Hebron Institute of Research (VHIR), together with the Innovative Medicine Initiative (IMI) held an Infoday. The main objective of this event was to show more in the details all the future call for proposals of the Public Private Partnership. To start with, Dr. Thomas Eichholtz, CSO and Corporate Director of R&amp;D at Almirall, presented the dynamics behind EFPIA and the call for proposals). He was followed by Dr.Eva Molero, CEO at Synapse Research Management Partners, who gave the partipants more details about real IMI projects, and keys to successful participation and management of such projects. Dr. Marta Gomez Quintanilla, Spanish representative in IMI 2 from CDTI, showed the Spanish participation in IMI so far, and also insisted on the need to be more proactive, and participate more actively in future calls and projects. After the coffee break, Dr. Magda Gunn, from the IMI executive office, explained very clearly the rules and framework of IMI 2, giving tips on the dos and donts in the application process. Participants from different research institutes could discuss and exchange over the lunch break. Then, more insight on the future topics to come were given by Dr. Magda Gunn (IMI) together with Dr. Nima Behkami, Strategic Alliance director at MSD. Dr. Farid Bidgoli, MSD Real World Evidence Manager, also gave a bit more detail on the work they are currently carrying on. Finally, a specific session on venture capital closed the day. Dr. Rémi Droller, Managing partner at Kurma Partners, together with Dr. Nima Behkami led toward a discussion on the potential of future businesses supported by VC in the biomedical field. </td></tr></table>comunica@vhir.org (VHIR)Fri, 28 Nov 2014 00:00:00 GMTThe Spanish version of the Gut Microbiota Worldwatch web has been released (28/11/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=250&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0250\2014_0250_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The ‘Gut Microbiota &amp; Health Section’ of the European Society Neurogastroenterology and Motility (ESNM), has released the Spanish version of the Gut Microbiota Worldwatch web. The web’s aim is to bring closer the importance for health and life quality of the gut microbiota (or intestinal bacteria) to the society and the media, and of course, to expand the knowledge about the issue. The Gut Microbiota Worldwatch’s President is Dr. Fernando Azpiroz, head of the Physiology and Pathophysiology of the Digestive Tract group at Vall d’Hebron Institute of Research (VHIR), and also head of the ESNM Gut Microbiota &amp; Health section, member of the UEG-United European Gastroenterology. Dr. Azpiroz emphasizes that “it is important for people to know the activity of the universe of bacteria they host in their guts and its key role for many physiological functions that our body is not capable of doing by itself, as some fiber digestion or some vitamin production, among others”. He also assures that if we care about our intestinal microbiota “it will take care of us, helping us protect our health and life quality”. Secondly, Dr. Francisco Guarner, researcher of the same group in VHIR, is a member of the experts’ board, contributing with his knowledge in the fields of intestinal mucosa, inflammatory bowel disease and probiotics, among others. He is the leader of the MetaHit Project in Spain whose goal is to associate bacterial genes with human health and diseases. The web is a powerful and extensive source for gut microbiota information online, with content selected from this experts’ platform and adapted for easier accessibility for a non-scientific audience. The content can also be found on their Twitter and Facebook accounts. </td></tr></table>comunica@vhir.org (VHIR)Fri, 28 Nov 2014 00:00:00 GMTThe College of Nursing of Barcelona has granted two projects of the Health Care research group (27/11/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=243&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0243\2014_0243_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The College of Nursing of Barcelona has granted two out of the nine aids of research to two predoctoral researchers of the Health Care research group, led by Dr. Carmen Fuentelsaz at Vall d’Hebron Institute of Research (VHIR). The nurse Esperanza Zuriguel leads the first project entitled “Evaluation of the critical thinking among nursing professionals, according to the Alfaro-LeFevre circular model”. The aim of her research, funded with 7,260 euros, is to elaborate a test to assess the critical thinking of the nursing staff, and to analyze its validity and reliability. The second project, called “Therapeutic adherence in adolescents, exploring opinions and experiences”, is led by the nurse Maria Luisa Cebrián and has been endowed with 2,601 euros. The objective of her study is to know the everyday experiences of adolescents who have underwent renal transplant, have diabetes or cystic fibrosis. She will also gather information about the vision of the young people concerning the medical and family attention received, as well as their proposals for improvement. </td></tr></table>comunica@vhir.org (VHIR)Thu, 27 Nov 2014 00:00:00 GMTVall d'Hebron hosted an international symposium of neuromonitoring and neurocritical patients (25/11/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=242&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0242\2014_0242_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The Neurotraumatology and Neurosurgery Unit (UNINN) at Vall d’Hebron Institute of Research (VHIR) organized the XVI International Symposium on Neuromonitoring and Neurocritical Patients, which took place in Barcelona from the 18 to the 22 of November. During 5 days, the Altimara Hotel was the meeting point of more than 450 multidisciplinary professionals in the diagnosis and treatment of neurocritical patients and those with traumatic brain injury. The opening lecture of the symposium was carried out by Dr. Douglas H. Smith, Director of the Penn Center for Brain Injury and Repair of the Pennsylvania University. He talked about diffuse axonal damage after traumatic brain injury. The congress also included the XI Course on nursing care in neurocritical patients, accredited by the Consell Català de Formació Continuada de les Professions Sanitàries. </td></tr></table>comunica@vhir.org (VHIR)Tue, 25 Nov 2014 00:00:00 GMTResearchers identify a gene associated with susceptibility to cervical artery dissection (24/11/2014)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2014&num=240&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0240\2014_0240_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Researchers from the International Stroke Genetics Consortium, in which participate Dr. Joan Montaner and Dr. Israel Fernández Cadenas from the Neurovascular Diseases group at Vall d’Hebron Institute of Research (VHIR), have discovered the association of a gene, called PHACTR1, with the risk of suffering cervical artery dissection. The results have been published in Nature Genetics. European and American researchers screened the entire genome of 1,400 patients with cervical artery dissection, some of them treated at Vall d’Hebron, and 14,000 referents without this disease. The aim of the study was to identify genes predisposing to this disease in order to better understand its mechanisms and improve prevention strategies. Thanks to this in-depth analysis, which is the largest carried out ever, Dr. Israel Fernández Cadenas, researchers from VHIR and the Fundació de la Docència i Recerca MutuaTerrassa, assures that they have discovered that “individuals carrying a certain genetic variant in the PHACTR1 gene are more likely to suffer this disease that represents one of the main causes of stroke among young people”. In a previous study in which also participated VHIR researchers, this genetic variant had already been associated with people with higher risk of suffering migraine. It was known that migraine was a risk factor to suffer cervical artery dissection, but there was not any biological connection between these two diseases. Cervical artery dissection is caused by a tear in a brain supplying artery wall (carotid or vertebral) that can lead to compression of adjacent nerves and to blood clotting within the artery, potentially causing occlusion of downstream vessels and brain infarction. Despite its low prevalence –it affects 2,6 out of 100,000 people, it has serious effects in the health of the survivors. According to Dr. Joan Montaner, “understanding the mechanisms by which this region of the genome appears to influence key vascular fun</td></tr></table>comunica@vhir.org (VHIR)Mon, 24 Nov 2014 00:00:00 GMTVHIR celebrates 20 years of excellence in research (21/11/2014)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2014&num=238&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0238\2014_0238_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Vall d’Hebron Institute of Research (VHIR) celebrated its 20th anniversary with an academic event that took place on Friday at the Pavelló Docent building, in front of over 200 people who are part of its history. On Thursday evening, promoters and authorities that participated in VHIR’s foundation, as well as donors, private companies who support the Instititute and technological partners, participated in an institutional dinner at Cosmocaixa. In both events, VHIR presented a video of its history. The academic event paid tribute to the key researchers in the foundation of the Institute: Dr. Simó Schwartz, HUVH’s first Research Director, Dr. Jordi Soler i Soler, former head of the Cardiology Service, Dr. Joan Ramon Malagelada, former head of the Gastroenterology Service, Dr. Jaume Guàrdia, former head of the Liver Diseases Group, and Dr. Àngel Ballabriga (1920-2008), former Director of the Children’s Hospital. Special mention was also given to people who have contributed to the center’s management during the past 20 years. This would be the case of former directors, –Dr. Carles Miquel, Dr. David García Dorado, Dr. José María Sáez as a posthumous title, and Dr. Juan Emilio Feliu– Trustees’ presidents or vice-presidents –Marina Geli, Dr. José Luis Sancho, and Dr. Jaume Raventós– and presidents of the Scientific Internal Committee that still are connected to VHIR –<span style=</td></tr></table>comunica@vhir.org (VHIR)Fri, 21 Nov 2014 00:00:00 GMTMutual Médica grants a study conducted by Dr. Marc Ramentol (19/11/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=241&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0241\2014_0241_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Dr. Marc Ramentol, researcher from the Systemic Diseases group at Vall d’Hebron Institute of Research (VHIR), has been granted with the Mutual Médica 2014 call, endowed with 4,000 euros, to investigate whether the persistent symptoms in the remission phase of Churg-Strauss syndrome are caused by an autoimmune expression of the disease. In the ceremony award, VHIR researcher highlighted the “rigorousness and the impartiality of the jury in the selection of the projects submitted, which means a great reputation for the young researchers awarded”. The eosinophilic granulomatosis with polyangiitis or Churg-Strauss syndrome is a systemic rare disease, with a prevalence of 2-6 cases out of one million people, which usually appears in patients who had previously suffered allergic asthma. </td></tr></table>comunica@vhir.org (VHIR)Wed, 19 Nov 2014 00:00:00 GMTVHIR's biobank at a doctor's click (19/11/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=237&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0237\2014_0237_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The biobank from the Vall d’Hebron University Hospital has implemented a new system in order to ease and speed up the reception of blood and urine samples extracted at the hospital in order to use them in research. This new proceeding, which is integrated in the hospital’s circuit, makes easier for the doctor to ask for a Biobank analysis of a sample, as it’s only one click away, and always with the patients consent. Thanks to this new system, the samples will arrive correctly labeled and work will be easier for the researchers, who were the ones in charge of asking the medical staff to extract and send the samples for their studies. The Cardiocirculatory Pathology group, headed by Dr. David García-Dorado, is already taking profit of this system. Actually, the Cardiology Bank of the Biobank is integrated within  healthcare and research activity from the Cardiology service and is a key piece of the PRECISED project; an integrated excellence project from Instituto de Salud Carlos III, in which eight VHIR groups work to prevent isquemic cardiovascular accidents in diabetic patients. For Dr. García-Dorado, the start of the Cardiology Bank “opens new horizons for cardiovascular research in the molecular medicine era, which is a remarkable landmark in our group’s history”. </td></tr></table>comunica@vhir.org (VHIR)Wed, 19 Nov 2014 00:00:00 GMTThe Health Care research group receives the prize to the best oral communication in the 18th International Nursing Research Conference (18/11/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=239&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0239\2014_0239_IMATGE.JPG" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The Health Care group research group, led by Dr. Carmen Fuentelsaz, has been awarded the best oral communication in the 18th International Nursing Research Conference, held in Vitoria-Gasteiz. The award-winning work, “Blood extractions in critical patients as a cause of&nbsp; anemization”, is the fruit of six years of work at VHIR under the supervision of Anabel Solsona, Maria del Mar Eseverri, Mercedes Garrido, Maria Alba Riera, Jordi Gómez, Montserrat Lolo, Maria Agustina Paricio, Dina Butrón and Elisabeth Gallart. The Conference, organized by the Health Care research unit at the Instituto de Salud Carlos III, is the most important meeting in health care research taking place in Spain. In the present edition 433 research projects were presented, almost all of them developed by nursing professionals from 23 different countries, amongst which Catalunya stands out as the one that presented more projects, with a total of 77. </td></tr></table>comunica@vhir.org (VHIR)Tue, 18 Nov 2014 00:00:00 GMTSOM Biotech and the Vall d'Hebron Hospital have initiated a clinical trial in patients using a new repositioned drug for amyloidosis (18/11/2014)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2014&num=235&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0235\2014_0235_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> SOM Biotech, located at the Parc Científic de Barcelona, has initiated the clinical phase of an innovative oral therapy for transthyretin amyloidosis (ATTR): compound SOM0226, a reprofiled drug developed entirely by the biopharmaceutical company. The phase IIa proof-of-concept trial in humans is being conducted at the Vall d'Hebron University Hospital, coordinated by Dr. Josep Gámez from the Peripheral Nervous System research group, and the treatment has already been administered to the first patients. The hospital will assume, jointly with the biotech, the risks and return on investment of the development of the drug, with the recent support from the Spanish Ministry of Economy. Transthyretin amyloidosis is a rare disabling disease with a severe prognosis that primarily affects the peripheral nervous system and the heart and, in some cases, is inherited from parents to children. The disease develops when the liver and other parts of the body produce the mutated protein transthyretin (TTR), causing a number of aggregates that are deposited into multiple organs. This excessive accumulation of protein, known as amyloid deposits,causes local cell damage that presents with a variety of clinical symptoms. These symptoms include severe cardiac and neurological problems that lead to the death of the patient within a period of 5 to 15 years. “Currently there is no other drug undergoing marketing approval for transthyretin amyloidosis in Europe. The only treatment available is a drug discovered in the United States (with the exorbitant price of more than 140,000 € per patient and per year) and liver transplantation, suitable only for a particular population group and with very high social and health costs", says Dr. Raúl Insa, founder and CEO of SOM Biotech. SOM0226 is a potent inhibitor of the amyloidogenic process with an innovative dual mechanism of action: as stabilizer of the transthyretin protein and disruptor of the fibers once they are deposited into the tissues. To cut it short, it stops progression and reverts the disease. This drug may also be effective against the 4 variants of transthyretin amyloidosis - polyneuropathic, cardiac, senile systemic and the CNS selective - including the more advanced stages of the disease. As a consequence, "this new therapeutic alternative will not only be able to confront Transthyretin amyloidosis but will also be able to prevent its progression, avoiding the formation of amyloid fibers”, remarks Dr. Gámez. </td></tr></table>comunica@vhir.org (VHIR)Tue, 18 Nov 2014 00:00:00 GMTVall d'Hebron researchers participate in the annual meeting of the REIPI (18/11/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=236&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0236\2014_0236_IMATGE.bmp" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Researchers from the groups of infectious diseases and microbiology at the Vall d’Hebron Institute of Research (VHIR) have participated in the annual meeting of the Spanish net of research in infectious pathology (REIPI). In the meeting, that has reached its seventh edition and this year coincided with the European Antibiotic Awareness Day, experts discussed the recommendations of the European Centre for Disease Prevention and Control about the prudent use of antibiotics. This meeting is an opportunity to launch a global appeal for the problem of antibiotic resistance. </td></tr></table>comunica@vhir.org (VHIR)Tue, 18 Nov 2014 00:00:00 GMTExperts in congenital bone marrow failure meet in VHIR (17/11/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=234&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0234\2014_0234_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Over 70 experts in bone marrow failure field, both national and international, met last Friday, 14th November, in the XXth Pediatric Oncology and Hematology Update Course organized by the Vall d’hebron Institut de Recerca (VHIR). The specialists addressed the latest news in research and clinical practice of these illnesses, deepening the knowledge and diagnostic of population under the risk of suffering cancer. The Research team in Child Cancer, headed by Dr. Josep Sánchez de Toledo, organized once again this meeting, reference in the field. The congress day concluded with Body-Cell Percussion’s performance, by Santi Serratosa and Mariona Castells.  </td></tr></table>comunica@vhir.org (VHIR)Mon, 17 Nov 2014 00:00:00 GMTVHIR researchers discover why the individuals with Down Syndrome have more predisposition to suffer autoimmune diseases (12/11/2014)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2014&num=233&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0233\2014_0233_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> A team of researchers of the Immunology group at Vall d’Hebron Institute of Research (VHIR) have discovered that an autoimmune regulator protein, called AIRE, is less expressed in individuals with Down Syndrome. This finding explains why the people with this syndrome have more predisposition to suffer autoimmune diseases. For the study, published in the Journal of Immunology, VHIR researchers used the major collection of thymus samples collected until now. Specifically, they analyzed samples from 19 individuals with Down Syndrome and congenital heart disease, collected since 1995 at the Pediatric Surgery unit of the Vall d’Hebron University Hospital. All thymus were removed following cardiac surgery because in this type of interventions the organ can’t be reintroduced. All samples were compared with the samples of patients with congenital heart disease but without Down Syndrome. The AIRE protein is codified on chromosome 21, which is tripled in individuals with Down Syndrome. Despite having three copies of the chromosome, they have more predisposition to suffer autoimmune diseases such as diabetes, celiac disease and hypothyroidism. To determine which is the role of AIRE in these individuals, Vall d’Hebron researchers analyzed its expression in the thymus. “Contrary to what we expected, we saw that in patients with Down Syndrome the protein is expressed in lower levels that in the rest of the people”, assured Dr. Roger Colobran, main author of the study. As a consequence, the expression of the specific genes that depend on this protein is also reduced, and this produces the central tolerance failure that takes place in the thymus. The origin of many autoimmune diseases is in the thymus, which is the organ of the immune system where the T lymphocytes, that coordinate the immune response, are developed. AIRE controls the mechanism that educates the T lymphocytes to attack external organisms such as virus, bacteria, fungus or parasites, instead of the own cells of the body. However, when this protein is less expressed, there is a central tolerance failure and T cells attack the own cells, which can cause ultimately an autoimmune disease. </td></tr></table>comunica@vhir.org (VHIR)Wed, 12 Nov 2014 00:00:00 GMTCAMFIC allocates the 0.7% of its budget on a project led by VHIR and PROSICS in Angola (12/11/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=176&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0176\2014_0176_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The Catalan Society for Family and Community Medicine (CAMIFIC) has donated nearly 12,000 euros, which is the 0.7% of its budget, to the project “Improvement of the treatment and quality of life of patients with tuberculosis in an area of Angola with high prevalence of the disease”, led by researchers from Vall d’Hebron Institute of Research (VHIR) and the International Health Program of the Catalan Institute of Health (PROSICS). The society concluded in a statement that the project was awarded for its research dimension, its commitment to telemedicine and its orientation towards the health co-development. The study is carried out at VHIR by the groups of Infectious Diseases and Microbiology. Since 2008, researchers and clinicians from Vall d’Hebron have worked closely with the Nossa Senhora da Paz Hospital, located in the centre-east of Angola. Since then, they are maintaining a telemedicine program to share clinical cases, and conducting several studies about the resistance to tuberculosis, the epidemiology of schistosomiasis, and the relationship between malaria and child mortality. A couple of months ago, they installed in Angola the first automatic system to diagnose multidrug-resistant tuberculosis, thanks to an agreement with the Probitas Foundation. </td></tr></table>comunica@vhir.org (VHIR)Wed, 12 Nov 2014 00:00:00 GMTDr. Josep Vaqué is awarded with the Semmelweis prize (11/11/2014)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2014&num=232&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0232\2014_0232_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Dr. Josep Vaqué, researcher of the Epidemiology and Public Health group at Vall d’Hebron Institute of Research (VHIR) and consultant physician of the same service at the hospital, has received the Semmelweis prize by the Spanish society of preventive medicine, public health and hygiene. The organization has awarded him for his study on the prevalence of hospital-acquired infections in Spain and for his commitment with the development and consolidation of the scientific society. He has coordinated since 1990 this annual study that is carried out in nearly 260 Spanish hospitals to determine the impact of the nosocomial infections in each centre. During the award ceremony, hosted last Friday at the Spanish Department of Health, Social Policy and Equality, Dr. Vaqué assured that “the EPINE study has become a very useful tool for the management of the hospitals, to improve the quality in the health care, and to ease the training of the staff in terms of surveillance, prevention and the control of nosocomial infections”. According to the latest results of the EPINE study, the 5.6% of the inpatients in 2014 got infected in the hospital, compared with the 8.5% in 1990. For Dr. Vaqué, these results show that “hospitals offer every year more security and quality in the control of nosocomial infections, which are still a common problem”. </td></tr></table>comunica@vhir.org (VHIR)Tue, 11 Nov 2014 00:00:00 GMTDr. Schwartz participates in the development of a strategic plan for innovation in nanotechnology in Argentina (06/11/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=231&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0231\2014_0231_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Dr. Simó Schwartz, coordinator of the CIBBIM-Nanomedicine at the Vall d’Hebron Institute of Research (VHIR), has advised the government of Argentina to develop a strategic plan of innovation in the field of nanomedicine and nanotechnology. The international consortium that has guided the government is also participated by the Institut de Bioenginyeria de Catalunya and the Universidad Nacional del Mar del Plata. After identifying the priority lines of research, development and innovations in this field, VHIR researchers have suggested specific action lines as well as political instruments required to implement them through the National plan of Science, Technology and Innovation 2005-2030. Among the main recommendations, there is the creation of national centers, the promotion of clusters, increasing public investments in equipment and R&amp;D&amp;I projects, promotion of entrepreneurship, speeding up import procedures, and the implementation of strategic monitoring systems to identify and create opportunities. Dr. Schwartz will also participate in the follow up of the project, which has received the technical support of IALE Tecnología, and has been funded by the Argentine government and the World Bank. </td></tr></table>comunica@vhir.org (VHIR)Thu, 6 Nov 2014 00:00:00 GMTVHIR is awarded with two 'Premios Mejores Ideas 2014' (04/11/2014)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2014&num=230&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0230\2014_0230_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Dr. Ferran Morell, head of the Pneumology group at Vall d’Hebron Institute of Research (VHIR), was awarded with one of the “Premios Mejores Ideas 2014”, by Diario Médico, for the discovery of one of the causes of the idiopathic pulmonary fibrosis. The journal specialized in health also awarded a pioneer surgery carried out at the Vall d’Hebron Hospital and led by Dr. David García Dorado, head of the Cardiocirculatory Pathology group at VHIR. The research conducted by Dr. Morell determined that one of the main causes of the idiopathic pulmonary fibrosis is the exposure of occult avian antigens from commonly used feather bedding (eiderdown and pillows), as well as the exposure to birds and fungi in little but persistent quantities. These surprising results, published in The Lancet Respiratory Medicine, will help the prevention and early detection of this pathology, avoiding advanced stages. On the other hand, Dr. García Dorado coordinated a surgery on a 22 weeks’ pregnant woman, who suffered a congenital heart disease and was wearing a prosthesis that replaced the aortic valve. The prosthesis failed by the stress of the heart during the pregnancy, and consequently, she suffered heart failure and a severe stenosis that put her life and the fetus’ life at risk. The medical team successfully implemented an aortic prosthesis inside the prosthesis that she was already wearing, in order to repair it.  The Catalan national theater (TNC) hosted on Monday the XIII edition of these prizes that recognize outstanding institutions and professionals in the field of healthcare in the last year. Among the winners, the former responsible of the Alzheimer’s group at VHIR, Dr. Mercè Boada, was awarded for starting a phase III clinical trial that could modify the course of the disease and stop the cognitive impairment. </td></tr></table>comunica@vhir.org (VHIR)Tue, 4 Nov 2014 00:00:00 GMTThere are whishes that change the world (03/11/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=229&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0229\2014_0229_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The Plaza de Los Pinazo of Valencia will host until November 4, the campaign “There are whishes that change the world” by Legado Solidario. Vall d’Hebron Institute of Research (VHIR) participates in this project with the aim to disseminate the possibility of leaving bequests and legacies to charities and nonprofit organizations. These types of donations have the aim to keep the commitment of those who die and want to support any of the 24 entities associated to the campaign, such as VHIR. The procedure that must be followed to formalize the legacy is inexpensive and simple, and respects the rights of the heirs. The image that represents VHIR is a pregnant woman who holds a picture of a newborn who clutches his parents hand with the slogan “Your legacy will give life to others”. Since the participation of VHIR in the campaign in 2012, 4 people have contributed to the biomedical research of excellence led at Vall d’Hebron, with two bequests and legacies.&nbsp; herencias. </td></tr></table>comunica@vhir.org (VHIR)Mon, 3 Nov 2014 00:00:00 GMTLa Marató de TV3 funds 5 projects in which VHIR participates (30/10/2014)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2014&num=228&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0228\2014_0228_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> La Marató de TV3 on Neurodegenerative Diseases will fund 5 projects that will be carried out at the Vall d’Hebron Institute of Research (VHIR) and other research centers. A total of 44 research projects of scientific excellence will be funded with the 11 million euros raised in the 2013 edition. From the 5 projects granted, VHIR will lead 2: “Efecte terapèutic de liposomes conjugats a proteïna ApoJ/Clusterin recombinant en models experimentals de malaltia d'Alzheimer” Principal investigator: Dr. Mar Hernández-Guillamon, researcher of the Neurovascular Diseases group. Budget: 200,000 euros “El paper de la reelina en la cruïlla dels mecanismes moleculars de la malaltia d’Alzheimer: taupatia, toxicitat de l’amiloide i transmissibilitat” Principal Investigator: Dr. Lluís Pujadas, researcher of the Alzheimer’s group. Collaborator: Dr. José María Delgado, from the Universidad Pablo de Olavide de Sevilla Budget: 299.943 euros Besides these projects, VHIR will collaborate in 3: “Desxifrant la relació entre la reactivitat des astròcits i el dany neuronal en la malaltia d'Alzheimer” <span style=" font-size: 8pt; font-family: 'Verdana', 'Geneva', sans-serif; font-style: normal; font-weight: normal; color: #555555; background-color: transparent; tex</td></tr></table>comunica@vhir.org (VHIR)Thu, 30 Oct 2014 00:00:00 GMTVHIR wins Best in Class 2014 to the best research and innovation center (29/10/2014)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2014&num=226&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0226\2014_0226_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Vall d'Hebron Institute of Research (VHIR) has received the Best in Class award to the best research and innovation center, one of the prizes organized by the journal Gaceta Médica and the Cátedra de Innovación y Gestión Sanitaria de la Universidad Rey Juan Carlos. The Unit of transplantations of haemopoietic progenitors at Vall d'Hebron University Hospital (HUVH) and the Multiple Sclerosis Center (Cemcat) also have been awarded in a ceremony in which were represented the best hospitals of Spain. This award fits perfectly with the aim of VHIR, which mission describes it as an institution that promotes and developes not only research but also biomedical innovation. VHIR does research to improve people's lives, and its researchers work to transfer to the society the knowledge they got investigating in the&nbsp; labs. Their results don't stay in the labs, but seek to be applied in patients in mid term. Dr. Joan Comella, VHIR's director, received the award in a cerimony that took place in the World Trade Center of Barcelona with the presence of the Catalan Health Minister, Dr. Boi Ruiz. </td></tr></table>comunica@vhir.org (VHIR)Wed, 29 Oct 2014 00:00:00 GMTDr. Ramón y Cajal has entered the Spanish Royal Academy of Doctors as a full member (29/10/2014)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2014&num=227&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0227\2014_0227_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Dr. Santiago Ramón y Cajal, head of the Molecular Pathology Service and group at the Vall d’Hebron Institute of Research (VHIR), has entered the Spanish Royal Academy of Doctors as full member. The topic chosen for his speech was the challenge of the pathological and molecular heterogeneity of cancer, and the new paradigms of the research. In his speech, he reviewed the research lines that his group has developed during the last years, as well as the most relevant advances in this field. He also suggested a change in the structure of the research, based in the creation of multidisciplinary teams in order to manage the knowledge, and to coordinate and monitor the projects. During his lecture, Dr. Ramón y Cajal also explained that the research is advancing a lot in the knowledge of cancer. In fact in the field of Molecular Pathology, researchers are continuously describing new variants of tumors, and in the field of molecular biology, they are identifying genetic and biochemical alterations. </td></tr></table>comunica@vhir.org (VHIR)Wed, 29 Oct 2014 00:00:00 GMTDr. Laura Audí new president of the European Society for Paediatric Endocrinology (28/10/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=225&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0225\2014_0225_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Dr. Laura Audí, researcher of the Paediatric Endocrinology group at the Vall d’Hebron Institute of Research (VHIR), has been appointed president of the European Society for Paediatric Endocrinology (ESPE) until October 2015. She will act as a president in the meetings of the board of directors of this society that involves hundreds of experts in diseases related to growth, puberty, sexual development problems and other disorders of the hormone producing glands of the body. Her group has been a member of the ESPE for the last 40 years. The society was founded in 1962 with the aim to promote the highest levels of clinical care for infants, children and adolescents with endocrine problems throughout the world, including in less advantaged areas. Dr. Audí will also organize the next ESPE annual meeting, which is the reference meeting point in this field around the world, from the 1st to the 3rd of October 2015. The annual meeting will be hosted for the first time in Barcelona with the theme “improving patient care: a pluridisciplinary dialogue”. It is expected that more than 3,000 professionals will have the opportunity to exchange and listen to the last discoveries and new perspectives in this field, as they did in the 53rd edition that took place this year in Dublin, Ireland. </td></tr></table>comunica@vhir.org (VHIR)Tue, 28 Oct 2014 00:00:00 GMTThe Duchenne Parent Project Association awards a grant to VHIR researchers (28/10/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=134&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0134\2014_0134_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The Duchenne Parent Project Association awarded on Tuesday one of the three grants for research projects about Becker and Duchenne Muscular Distrophy (DMD) to a team participated by Vall d’Hebron Institut de Recerca (VHIR) researchers, for the project “Study of the efficiency of drugs capable of restoring the dystrophin expression in myoblasts of patients suffering from DMD with nonsense mutations, analysis of the causes that condition the variability in the response and evaluation of strategies to increase this efficiency in human myoblasts and in the mdx mouse”. The project lasts 2 years and the aid amount is 25,000 euros for the first year and the same for the second, after evaluating the results from the first year. From the VHIR, the team counts on the Drs. Francina Munell, María José Pérez and Silvia Ferrer&nbsp; (Pediatric Neurology Unit), Jordi Barquinero (Advanced Therapy Unit), Elena Martínez-Sáez (Molecular Pathology group), and also the project will be developed together with the Hospital Universitari Vall d’Hebron (HUVH) and the IQS’ Grup d’Enginyeria de Materials (GEMAT), with the participation of Drs. Salvador Borros, David Sánchez-García and Ofir Arad. The project focuses in the analysis of the variability of the response of the new therapies destined to reestablish the dystrophin expression in patients suffering from DMD, specifically the one focused on correcting the nonsense mutations with PCT124 (Ataluren). The aim is to understand why some of these patients respond less to these treatments and to design new strategies destined to correct these problems. Describing the project, the researchers point that “the best way to approach it is through the collaboration of centers that have experience in neuromuscular diseases in a clinical and translational level with centers that have experience in disciplines that allow to address new mecanisms and strategies”. The DMD is considered a rare disease<span style=" font-size: 8pt; font-family: 'Verdana', 'Geneva', sans-s</td></tr></table>comunica@vhir.org (VHIR)Tue, 28 Oct 2014 00:00:00 GMTDonation for ALS, in memory of Francesc Bonvehí (27/10/2014)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2014&num=224&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0224\2014_0224_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Friends and relatives of Francesc Bonvehí donated 1,288 euros for the research in Amyotrophic Lateral Sclerosis (ALS) carried out by the Peripheral Nervous System group, led by Dr. Josep Gámez at Vall d’Hebron Institute of Research (VHIR). Francesc Bonvehí i Trench had ALS and died because of this disease just a few hours after the collective ice bucket challenge that he promoted at the main square of Manresa at the end of September. That day, many friends and relatives got wet for his cause, many of them from his association “Grup Sardanista Dintre el Bosc” and from the “Geganters de Manresa”, in which he was the vice-president. The funds raised at the party were donated to the VHIR and to the Miquel Valls Foundation, which is a non-profit organization with the aim to improve the quality of life of patients with ALS. Dr. Gámez group is currently working on three different research lines dedicated to the study of molecular mechanisms and genetic mutations of the disease. The group is also part of ALSUntangled, an international network of clinical experts with the aim of offering alternative or off-label ALS treatments. Besides the research team, the Vall d’Hebron University Hospital has an interdisciplinary unit devoted to the care of ALS patients, which serve nearly 100 out of the 400 affected that are in Catalunya. The cause of ALS is unknown and there is no cure or treatment available. It is a debilitating disease characterized by the loss of motor neurons which cause rapidly progressive weakness, muscle atrophy and the death of the patients by breathing failure. </td></tr></table>comunica@vhir.org (VHIR)Mon, 27 Oct 2014 00:00:00 GMT"If you are a true scientist and confident about your data you will be the winner" (24/10/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=223&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0223\2014_0223_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The Nobel Prize laureate in Medicine in 2005, Professor Barry J. Marshall, is the responsible of the paradigm shift in the treatment of stomach ulcers. For many years, the scientific community associated this disease with factors such as stress, and no one could conceive that bacteria could survive in the stomach. Prof. Marshall did it, but during 10 years he was much criticized. Eventually, he showed that the bacterium Helicobacter pylori is the cause of most peptic ulcers, and consequently, the disease can be cured with antibiotics.&nbsp; On October 19, Marshall gave the opening lecture of the World Health Summit 2014, where we met him to know more about his experience as a researcher. How did you feel when everybody said that you were wrong in that time? Were you frustrated, angry or just the opposite? My answer to that is that science is not a democracy. If you are a true scientist and you are confident about your own data, you don’t need to worry about everybody being against you. You know that eventually, you’ll be the winner. And the most simple, cost-effective solution to any problem is going to be the ultimate successful one. I knew that eventually everybody would want to use antibiotics. At that time, did you have the support of a PI or your boss? It took me two years of trying before I had any finding. And after that, I didn’t need any boss because I had my own money and my own salary from the Australian research funding agency. Peer review funding is good, but originally with a funny idea or strange theory you don’t have any peers, so you have to develop some collaborators or supporters. Then with the initial very small thing you do, that in my case was a post, you have a few supporters that will help you to talk to more senior people, who can mentor you, give you some advice and make suggestions. However, you don’t have to take the suggestions because they are often the guides. But that’s when you start, and that might connect you with the right networks. In my case, ultimately within two years, I had national and international supporters. In 1984 you drank a huge amount of helicobacters. What led you to do this? <span st</td></tr></table>comunica@vhir.org (VHIR)Fri, 24 Oct 2014 00:00:00 GMT"The recovery of Teresa Romero will foster the research in ebola" (23/10/2014)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2014&num=222&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0222\2014_0222_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Doctor Diana Pou, member of the Infectious Diseases group at Vall d’Hebron Institute of Research (VHIR) and the Catalan program for international health (PROSICS), is a consultant of the scientific committee of Ebola in Spain at the Instituto de Salud Carlos III (ISCIII) of the Spanish government. Pou worked in Africa with Médecins Sans Frontières for several periods in 9 years, and has experienced in first person 3 ebola outbreaks. For the specialist in tropical medicine, the recovery of the Spanish nurse assistant, Teresa Romero, “opens the door to the research in ebola”. According to the Spanish news agency EFE, she assured that pharmaceutical companies are who decide when will arrive the first drug for ebola. Nonetheless, since this case, “the expectations in the knowledge of the virus, the disease, the possible treatments and the vaccines have increased” Pou reported. The physician was interviewed in TV3 and 8TV, where she explained her experience as a consultant of the Spanish government. She also explained that there is still a long shot of new cases in Spain, and insisted on the need to manage what she considers an ‘epidemic of fear’ among the society. </td></tr></table>comunica@vhir.org (VHIR)Thu, 23 Oct 2014 00:00:00 GMTStudy in young male prisoners suggest that aggression can be reduced by treating ADHD (22/10/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=221&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0221\2014_0221_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> At an international meeting held by the Aggressotype Consortium in Mainz, Germany, researchers from King’s College and Imperial College London presented preliminary results from an on-going treatment study of ADHD in young male prisoners. A team of researchers from the group of Psychiatry, mental health and addictions, at the Vall d’Hebron Research Institute (VHIR), led by Dr. Josep Antoni Ramos-Quiroga, is participating in this study through the Aggressotype Consortium. The preliminary results show that 20% of the prisoners met clinical criteria for ADHD. After medical treatment with a long acting stimulant medication there was a large reduction in ADHD symptoms. Improvements with ability to focus attention, restless over activity and impulsive responding were accompanied by greater self-control of behavior and ability to engage positively in educational and rehabilitation programs. Participants reported being less frustrated, irritable and angry, and there was a reduction in aggressive incidents. Aggressotype is a large international consortium funded by the European Union consisting of 18 academic and 6 commercial partners. Aggressotype researchers aim to unravel the biological causes and mechanisms underlying aggression in ADHD and conduct disorder and also investigate how aggression can best be prevented and treated. In their annual meeting this October, the 60 researchers discussed the progress made during a successful first year of their 5-year project, with issues presented covering a wide range of disciplines. Aggressotype represents a unique mix of people with skills and expertise in neuropsychiatry, neuropsychology, preclinical animal and in vitro models, neuroimaging and neurochemistry, genetics and genomics, epigenetics, bioinformatics and biostatistics, clinical pharmacology, regulatory affairs, ethics, valorisation and project management. </td></tr></table>comunica@vhir.org (VHIR)Wed, 22 Oct 2014 00:00:00 GMTThe project 'Global Tele Rehabilitation System' improves the mobility of patients after a stroke (21/10/2014)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2014&num=220&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The Global Tele Rehabilitation System project (GTRS), promoted by the Vall d’Hebron Research Institute (VHIR) with the support of Fundación Vodafone España, has developed a solution for patients after suffering a stroke that allows them to do the rehabilitation at home under the control of a medical team. After a year and a half of trials, the initiative has concluded with excellent results. The solution, created by the I2Cat Foundation, consists on a series of personalized exercises presented as a game that patients have to follow in order to improve mobility on the parts affected after the stroke. The system records the exercises to facilitate the evolution of treatment and includes programmed videoconferences so that doctors and patients can chat about the rehabilitation process. The system, from the patient side, consists of a computer equipped with a touch screen, a Microsoft Kinect sensor and a mobile broadband internet connection provided by the 4G Vodafone network. The application has been used by 30 patients from different ages that have a disability because of a stroke, and they have followed a treatment during four weeks in each one of the 4 available devices. Besides the devices, the Occupational Therapy Unit at the Vall d’Hebron University Hospital (HUVH), as well as the rehabilitation team lead by Dr. Inmaculada Bori, have had a key role in the clinical follow-up of the cases. Patients are really satisfied with the results of the day-to-day treatment. Now the pilot study is over, all the equipment will be incorporated to the normal practice to keep being of use to new patients. They are also studying the possibility of establishing these equipment in different rehabilitation centers. The study, that has just concluded and its results will be presented in the next congress of the Sociedad Española de Neurología, has shown that the use at home of the system GTRS during 4 weeks induces a general improvement in the mobility of upper extremities of patients. All participants, patients and professionals, have coincided in valuing positively the tool and most of them regretted not being able to use it longer. Dr. Marc Ribó, neurologist at the Ictus Unit of the HUVH, ensures that the system is “a step forward, which makes rehabilitation easier and saves time and money for the patient and for the public health system”. The challenge now is that the system also improves the mobility on inferior extremities, as well as using it for other disabilities. </td></tr></table>comunica@vhir.org (VHIR)Tue, 21 Oct 2014 00:00:00 GMTThe race 'Nick Horta' raises 8,000 euros for hepatic cancer (21/10/2014)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2014&num=180&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0180\2014_0180_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The V Cursa Nick Sport d'Horta, the charity race that took place the September 21th and this year was dedicated to hepatic cancer at the Vall d’Hebron Institut de Recerca (VHIR), was a success with 1,000 runners registered and 8,000 euros raised for research on this disease, at VHIR. María José Moscoso, the promoter of the race, has given the cheque to VHIR's Director, Joan X. Comella, together with Gemma Flores, director of the Nick Sports center. Moscoso it’s been 9 months since she got a liver transplant at Vall d’Hebron, after she was diagnosed with hepatic cancer. The day of the race she gave a symbolic cheque to Dr. Ramon Charcho, head of the digestive transplants group at VHIR. “I feel that I must help all the people who have been with me and the Catalan public system of health”, said María José, that admitted that “I consider my duty to compensate somehow all the things that the doctors have done to keep me alive and healthy”. This is the reason why the last two years the charity race has dedicated all funds to the research at VHIR; the goal is to collect more funds than last year that raised nearly 5,000 euro. The main novelty for this year event was a free special race for young people and children with Down syndrome or any other disability that joined the race in the last 1.5km. </td></tr></table>comunica@vhir.org (VHIR)Tue, 21 Oct 2014 00:00:00 GMTVHIR researchers unveil the role of a key protein in the reparation of the damage caused by the solar radiation (16/10/2014)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2014&num=218&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0218\2014_0218_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Researchers of the Melanoma group at the Vall d’Hebron Institute of Research (VHIR), integrated by professionals from the services of Dermatology, Oncology and Pathology, and led by Dr. Juan Ángel Recio, discovered that a protein, called LKB1, is essential to trigger the process of reparation of the DNA damage caused by solar radiation.&nbsp; The landmark, published in Plos Genetics, paves the way for the use of the protein as a prognostic factor in patients with ultraviolet induced skin cancer. Ultraviolet radiation has been associated to the acquisition of different types of skin cancer and premature skin aging. It causes modifications in the genetic material of cells (DNA) that if not repaired properly will lead to a mutated DNA which might trigger the development of cancer. In fact, several studies conclude that people who overexposed to the sun during their childhood are more likely to develop melanoma at the age of 50 and above. For that reason, understanding the molecular basis of the ultraviolet-induced DNA damage response is important to elucidate the mechanisms of skin tumorigenesis. The aim of the study was to determine the causes that lead to the development of skin cancer due to ultraviolet radiation. Particularly, they wanted to unveil how LKB1, which is a mutant protein in humans, participates in these processes. Firstly, the authors used a UV-induced skin cancer mouse model, where one of the two Lkb1 gene alleles was deleted, and consequently the amounts of LKB1 protein was of half the normal levels. A single dose of ultraviolet radiation in Lkb1 neonate mice was enough to induce the quick development of squamous cell carcinomas, and this was associated to a deficient response in DNA damage repair. This single dose of radiation is the equivalent to three hours of exposure to the sun without any protection in summer. The results were surprising, Dr. Recio reported, because the animals developed skin cancer five months before the expected date: “mice with the protein inactivated in one allel developed, in just one month, a type of cancer that use to suffer farmers, fishermen or people who has been exposed to the sun for a long period in their life”, explained Dr. Recio. Moreover, cells harboring the damaged DNA were resistant to cell death (apoptosis). Thus, as Dr. Recio said, lack of LKB1 promotes a double effect: “cells not only fail to repair the damage in their DNA, but they do not die, leading to the accumulation of mutated cells and the development of tumors”. The research team has obtained similar results (to be published soon) in two additional mouse models of melanoma, a much more lethal type of UV-induced skin cancer. In the near future, Dr. Recio’s team will be evaluating LKB1 as a prognostic risk factor for ultraviolet–induced skin cancer. They also are investigating the different factors that may alter LKB1 expression, with a particular emphasis in families with skin cancer predisposition or skin cancer history. </td></tr></table>comunica@vhir.org (VHIR)Thu, 16 Oct 2014 00:00:00 GMTTwo VHIR platforms become facilities of the Spanish Map of Singular Scientific and Technical Infrastructures (16/10/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=219&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0219\2014_0219_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The council of Political Science, Technology and Innovation approved the new so-called Spanish Map of Singular and Technical Infrastructures (ICTS) that, for the first time, includes two platforms of the Vall d’Hebron Institute of Research (VHIR). These platforms are the Area of Functional Validation and Preclinical Research (FVPR), managed by the CIBBIM-Nanomedicine, and the Molecular Imaging Platform, located in the Animal Facilities of the Institute. Both infrastructures are integrated in the Spanish network of biomedical research in bioengineering, biomaterials and nanomedicine (CIBER-BBN). The FVPR aims to provide the industry and other research groups with an optimum technical platform for testing new biomedical applications based on the nanotechnology from compounds for the treatment of specific diseases to new applications in diagnosis and imaging. One of the services of the FVPR is the Molecular Imaging Platform, established through the common efforts of CIBER-BBN, CIBBIM-Nanomedicina and VHIR, as a service to research groups and pharmaceutical companies. Its mission consists in provide the capacity to develop noninvasive optical image in vivo at cellular, molecular and functional level, including fluorescence and bioluminescence. Both services are part, together with 27 Spanish infrastructures, of the NANBIOSIS platform, which is devoted to produce and characterize nanomaterials, biomaterials and biomedical systems at the CIBER-BBN. This platform is oriented towards medical applications and aims to give an easy full service to researchers. It includes the design, production of biomaterials and nanomaterials, the characterization of these materials and tissues, and the development of medical devices and systems from a physical, chemical, functional, toxicological and biological point of view, including the preclinical validation (which is the part carried out at VHIR). The new map approved by the government has 29 ICTS that include a total of 59 infrastructures. All of them passed a rigorous assessment process and demonstrated their economic sustainability. </td></tr></table>comunica@vhir.org (VHIR)Thu, 16 Oct 2014 00:00:00 GMTThe town of Sant Mateu collaborates in the research against colorectal cancer (15/10/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=216&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0216\2014_0216_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The Mamma Mia musical, played in Sant Mateu by an amateur company from Vinaròs, beat the expectations of the organizers, who counted nearly 2,000 visitors. It is in fact a high number of people, taking into account that this town located in the Maestrat has more or less the same number of inhabitants. The tickets were free, but instead, the party committee asked for donations to support the research in colorectal cancer carried out at the Vall d’Hebron Institute of Research (VHIR). They raised more than 4.300 euros that will fund the research of the Molecular Oncology group at CIBBIM, led by Dr. Diego Arango. Dr. Arango received in his lab the members of the party committee, in order to thank them for the initiative and to tell them the research that he leads at VHIR. His group works in two main research lines: one focused in the biology of the disease with the objective to personalize treatments, and the other one aims to identify biomarkers to improve the survival of colorectal cancer patients. </td></tr></table>comunica@vhir.org (VHIR)Wed, 15 Oct 2014 00:00:00 GMTAnnals of Neurology recognizes a study by Dr Vila as 'paper of the year' (15/10/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=217&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0217\2014_0217_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The editorial board of the Annals of Neurology, the journal of the American Neurological Association, and its Editor-in-chief Prof. Clifford Saper, awarded the “Paper of the Year” prize to a study led by Dr. Miquel Vila, ICREA researcher, leader of the Neurodegenerative Diseases Group of the VHIR, and member of CIBERNED.&nbsp; The study shows that pathological forms of the alfa-synuclein protein present in the brain of deceased Parkinson Disease (PD) patients were capable of initiating a PD-like pathological process in mice and primates. For the authors, these findings provide new information on how the disease is initiated and amplified. The study, published in February 2014, in the Annals of Neurology, involved the participation of other CIBERNED groups from the University of Valencia and the University of Navarra, as well as researchers from the University of Bordeaux, France.&nbsp; The award will be presented during the next American Neurological Association meeting in Baltimore, Maryland, October 12-14.&nbsp; </td></tr></table>comunica@vhir.org (VHIR)Wed, 15 Oct 2014 00:00:00 GMTExperts in the application of genomics in biomedicine meet at VHIR (14/10/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=214&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0214\2014_0214_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The meeting “The impact of genomics in translational medicine: present view”, held last Monday October 13 in the Vall d’Hebron Institut de Recerca (VHIR), brought together a group of experts in the application of genomic techniques in biomedicine with two main objectives: bring these techniques closes to our community, and analyzing how they apply and the problems said application bring. The first speaker, Dr. Joaquín Dopazo, heaf of the group of Computational Genomics at the Centro de Investigación Príncipe Felipe (CIPF), explained to the researchers of the institute how they can use different sequencing techniques in order to identify pathological variables in the genome of the patients. After his speech, Dr. Ivo Gut, director of the Centro Nacional de Análisis Genómico, approached some international projects in which genomic information is key for the better understanding of rare diseases and cancer. The third speaker, Dr. Manel Esteller, director of the Epigenetic and Biology of Cancer program at IDIBELL, recalled that the genetic effects are just one small part of the molecular causes of the disease, and that massive epigenetic analysis can have an important diagnostic value. Finally, Dr. Xavier de la Cruz, head of the Translational Bioinformatics research group at VHIR, presented the techniques for the identification of pathological mutations to the sequencing problems, its limits and possibilities of improvement. <p style=" text-align: left; text-indent: 0px; padding: 0px </td></tr></table>comunica@vhir.org (VHIR)Tue, 14 Oct 2014 00:00:00 GMTA day of hope for patients with multiple myeloma (14/10/2014)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2014&num=215&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0215\2014_0215_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> More than a hundred patients with myeloma (bone marrow cancer) and their families took part on the 1st Meeting for patients in Spain, last Saturday in the Vall d’Hebron University Hospital, with the aim to open dialogue with the best researchers in the disease in Spain that are, also, among the world elite. The meeting was organized by Patient Power, the Vall d’Hebron Institute of Research (VHIR) and the Catalan Institute of Oncology. Doctors Mercè Gironella, responsible of Myeloma at the Vall d’Hebron Hospital and researcher at VHIR; Albert Oriol, from the Catalan Institute of Oncology; María Victoria Mateos, from the University Hospital of Salamanca; and Francesc Bosch, head of Hematology at the Vall d’Hebron Hospital and VHIR, sent an optimistic message. Dr Bosch explained that “at the rate we are going, we will be able to cure some cancers in 10 or 15 years”. Actually, treatments nowadays allow most of the patients a good quality of life during quite some years. Elisa, patient of myeloma for many years, explained that “I go ahead, have a normal life, even now that I have relapsed, and even at a time I lost my ability to walk”. Mercè, another patient, explained that it’s been 11 years since she was diagnosed and that she goes ahead “thanks to the doctors”. In the last years powerful medicine has been released that allow treating the patient once he or she relapses and, moreover, are less toxic than years ago. What is clear is that patients are now active part of the fight against the disease: “Before there was a tennis match between the doctor and the diseased; now it is a doubles match against the myeloma”<span style=" font-size: 8pt; </td></tr></table>comunica@vhir.org (VHIR)Tue, 14 Oct 2014 00:00:00 GMTVHIR selects Macrogen as the genomics service partner (13/10/2014)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2014&num=212&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0212\2014_0212_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The Vall d’Hebron Institute of Research and the world-leading Genomics services company Macrogen announced that they had signed a comprehensive Genomics service partnership agreement including Macrogen X-Genome (the Xpressway to Genome) services. According to this agreement, Macrogen will provide various Genomics services including both the capillary sequencing service and the state-of-art next-generation sequencing (NGS) service to VHIR researchers. This agreement reinforces VHIR’ scientific and technical support services in an effort to strengthen its researcher’s capacity to discover and implement novel diagnosis and treatment measures. In this sense, VHIR’s researchers will benefit from the Macrogen-VHIR special program based on Macrogen’s comprehensive Genomics service portfolio. VHIR’s staff, composed of 1.200 researchers (mostly clinicians), is aimed to achieve a direct translation from research to applications, with the final goal of offering Vall d’Hebron Hospital patients the benefit of the most advanced knowledge. By means of this agreement, Macrogen will partner VHIR to achieve its objective. In fact, Macrogen is the only European provider of the Illumina HiSeq X Ten sequencing system based large-scale Human whole-genome sequencing service, also known as Macrogen’s ‘X-genome (the Xpressway to Genome)’ service. Optimized for large-scale human genome analysis projects, the HiSeq X Ten sequencing system is capable of analyzing the genomes of 16 people within 3 days for a cost of less than 1,000 dollars, giving rise to expectations that it will pave the way to a new era of human genome sequencing. In January of this year, Macrogen became the first commercial service provider to sign a preferred supply agreement for the HiSeq X Ten system with Illumina. </td></tr></table>comunica@vhir.org (VHIR)Mon, 13 Oct 2014 00:00:00 GMTDr. Sanchez de Toledo, recognized with the highest distinction of Rotary International (13/10/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=213&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0213\2014_0213_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Rotary International has awarded the Paul Harris distinction to Dr. José Sánchez de Toledo, head of the Translational Researh in Child Cancer at the Vall d’Hebron Institute of Research (VHIR), as recognition to his scientific and human career dedicated to the cure of children with cancer, and beating the disease. The award is the highest recognition that Rotary International gives for business excellence, community service and professional career. The prize was presented last Thursday October 9 in Barcelona, in the context of the celebration of a charity dinner, to raise funds for the research group in child cancer at VHIR. Dr. Sánchez de Toledo gave a conference in the celebration titled “Research for children with cancer. A better future”. The organization brought together eminent people from the health field, public and private institutions, companies, rotary authorities and civil society in general. Dr. Sánchez de Toledo is Doctor in medicine and Surgery for the Universitat Autònoma de Barcelona (UAB). Nowadays he is chief of Pediatric Oncology and Hematology at the Vall d’Hebron University Hospital, head of the research group on child cancer at VHIR, and associated professor of pediatrics at UAB. The Service he leads was pioneer in Spain, in 1984, on performing bone marrow transplants on children. Since then, the transplant unit has realized more than 1,100 cell transplants, more than twice any other Spanish hospital. Among other recognitions, in 2012 he received the price to Professional Excellence that gives the Col·legi de Metges de Barcelona and was chosen Catalan of the Year 2012. </td></tr></table>comunica@vhir.org (VHIR)Mon, 13 Oct 2014 00:00:00 GMT